{
    "organizations": [],
    "uuid": "d4b671a1de92c3e3495f0846fe4708ec66ea9099",
    "author": "",
    "url": "https://www.reuters.com/article/brief-beigene-initiates-global-phase-2-t/brief-beigene-initiates-global-phase-2-trial-of-anti-pd-1-antibody-tislelizumab-in-patients-with-previously-treated-hepatocellular-carcinoma-idUSASC09VDE",
    "ord_in_thread": 0,
    "title": "BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News  32 AM / Updated 6 minutes ago BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma Reuters Staff 1 Min Read \nApril 10 (Reuters) - Beigene Ltd: \n* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T14:31:00.000+03:00",
    "crawled": "2018-04-10T14:45:30.031+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "updated",
        "minute",
        "ago",
        "initiate",
        "global",
        "phase",
        "trial",
        "antibody",
        "tislelizumab",
        "patient",
        "previously",
        "treated",
        "hepatocellular",
        "carcinoma",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "beigene",
        "ltd",
        "beigene",
        "initiate",
        "global",
        "phase",
        "trial",
        "antibody",
        "tislelizumab",
        "patient",
        "previously",
        "treated",
        "hepatocellular",
        "carcinoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}